Destiny Pharma upbeat on prospects for C. Difficile treatment
News release
by
Destiny Pharma PLC
London, UK
|
April 06, 2023 09:53 AM Eastern Daylight Time
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal.
Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
